Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Aslan, Ibrahim ^a   Kucuksayan, Ertan ^b   Aslan, Mutay ^b  

^a Antalya Education and Research Hospital   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

CETP; Diabetes mellitus; HDL; Insulin; LDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; LOW DENSITY LIPOPROTEIN; METFORMIN; PHENOL; PHENYLACETIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HYDROLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METFORMIN; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84876685849     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-54     Document Type: Article

References (42)

1. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, Diabetes Care 2005 28 12 2901 2907 10.2337/diacare.28.12.2901 16306552 (Pubitemid 43942922)
2. Insulin resistance and cardiovascular disease. Ginsberg HN, J Clin Invest 2000 106 4 453 458 10.1172/JCI10762 10953019 (Pubitemid 30666377)
3. Management of dyslipidemia in adults with diabetes. American Diabetes Association, Diabetes Care 2000 23 Suppl 1 57 S60 12017680
4. Atherogenic lipid phenotype in a general group of subjects. Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X, Arch Pathol Lab Med 2007 131 11 1679 1685 17979486 (Pubitemid 350077465)
5. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the scandinavian simvastatin survival study (4S). Pyrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, Diabetes Care 1997 20 4 614 620 10.2337/diacare.20.4.614 9096989 (Pubitemid 27143424)
6. Lipid lowering therapy in type 2 diabetes. Föger B, Wien Med Wochenschr 2011 161 11-12 289 296 21769710
7. Small low-density lipoprotein and small low-density lipoprotein/total low-density lipoprotein are closely associated with intima-media thickness of the carotid artery in Type 2 diabetic patients. Inukai T, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Inukai Y, Matsutomo R, Takebayashi K, Aso Y, J Diabetes Complications 2005 19 5 269 275 10.1016/j.jdiacomp.2005.03.002 16112502 (Pubitemid 41169824)
8. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Chapman MJ, Guérin M, Bruckert E, Eur Heart J 1998 19 Suppl A 24 A30 9519339
9. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. Gardner CD, Fortmann SP, Krauss RM, JAMA 1996 276 11 875 881 10.1001/jama.1996.03540110029028 8782636 (Pubitemid 26301606)
10. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. Syvänne M, Ahola M, Lahdenperä S, Kahri J, Kuusi T, Virtanen KS, Taskinen MR, J Lipid Res 1995 36 3 573 582 7775869
11. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ, Arterioscler Thromb Vasc Biol 2004 24 11 2181 2187 10.1161/01.ATV.0000146325. 93749.a8 15388521 (Pubitemid 39482449)
12. HDL functionality. Soran H, Hama S, Yadav R, Durrington PN, Curr Opin Lipidol 2012 23 4 353 366 10.1097/MOL.0b013e328355ca25 22732521
13. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J, Diabetes Care 2004 27 11 2597 2602 10.2337/diacare.27.11.2597 15504992 (Pubitemid 39441457)
14. AACE diabetes mellitus clinical practice guidelines task force american association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F, Endocr Pract 2007 13 1 68 10.4158/EP.13.S1.1 17613449
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
16. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP, Clin Chem 2001 47 2 266 274 11159775 (Pubitemid 32142925)
17. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD, Clin Chem 2005 51 12 2264 2273 10.1373/clinchem.2005.058404 16223884 (Pubitemid 41692569)
18. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS, Diabetes Obes Metab 2008 10 6 476 483 10.1111/j.1463-1326.2007.00733.x 17459096 (Pubitemid 351639090)
19. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Monnier L, Lapinski H, Colette C, Diabetes Care 2003 26 881 885 10.2337/diacare.26.3.881 12610053 (Pubitemid 36929359)
20. Postprandial hyperglycemia and diabetes complications: is it time to treat? Ceriello A, Diabetes 2005 54 1 7 10.2337/diabetes.54.1.1 15616004 (Pubitemid 40105088)
21. Lantus® Insulin glargine [rDNA origin] injection Bridgewater, NJ: Sanofi-Aventis Prescribing information. 2007
22. NovoLog® Insulin aspart [rDNA origin] injection Princeton, NJ: Novo Nordisk Inc Prescribing information. 2011
23. Humalog® Insulin lispro [rDNA origin] injection Indianapolis, IN: Eli Lilly and Company Prescribing information. 2011
24. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Morello CM, Int J Gen Med 2011 4 827 835 22267935
25. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Roach P, Clin Pharmacokinet 2008 47 595 610 10.2165/00003088-200847090-00003 18698880
26. Insulin glargine 4002 study investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Riddle MC, Rosenstock J, Gerich J, Diabetes Care 2003 26 3080 3086 10.2337/diacare.26.11.3080 14578243 (Pubitemid 37339502)
27. Statement by an american association of clinical endocrinologists/ american college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS, Endocr Pract 2009 15 540 559 10.4158/EP.15.6.540 19858063
28. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Noh YH, Lee SM, Kim EJ, Kim DY, Lee H, Lee JH, Lee JH, Park SY, Koo JH, Wang JH, Lim IJ, Choi SB, Diabetes Metab Res Rev 2008 24 5 384 391 10.1002/dmrr.849 18461633
29. AACE task force for developing diabetes comprehensive care plan. American association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, Endocr Pract 2011 17 Suppl 2 1 53 21849271
30. A1c-Derived average glucose study group. Translating the A1C assay into estimated average glucose values. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, Diabetes Care 2008 31 8 1473 1478 10.2337/dc08-0545 18540046
31. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. Rivellese AA, Patti L, Romano G, Innelli F, Di Marino L, Annuzzi G, Iavicoli M, Coronel GA, Riccardi G, J Clin Endocrinol Metab 2000 85 11 4188 4192 10.1210/jc.85.11.4188 11095452 (Pubitemid 32055371)
32. High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without/with intensive insulin therapy. Fukui T, Hirano T, Endocr J 2012 59 7 561 569 10.1507/endocrj.EJ11-0329 22504174
33. New molecular insights into CETP structure and function: a review. Charles MA, Kane JP, J Lipid Res 2012 53 8 1451 1458 10.1194/jlr.R027011 22679067
34. Insulin improves fasting and postprandial lipemia in type 2 diabetes. Geltner C, Lechleitner M, Föger B, Ritsch A, Drexel H, Patsch JR, Eur J Intern Med 2002 13 4 256 263 10.1016/S0953-6205(02)00038-9 12067822 (Pubitemid 34627056)
35. Increased cholesteryl ester transfer protein and changes in lipid metabolism from initiating insulin therapy. Ai M, Tanaka A, Baba T, Yui K, Numano F, Ann N Y Acad Sci 2001 947 356 361 11795290 (Pubitemid 34059935)
36. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Sparks JD, Phung TL, Bolognino M, Sparks CE, Biochem J 1996 313 Pt 2 567 574 8573094
37. Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD, J Biol Chem 1997 272 49 30693 30702 10.1074/jbc.272.49.30693 9388205 (Pubitemid 27527502)
38. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Sparks JD, Sparks CE, Adeli K, Arterioscler Thromb Vasc Biol 2012 32 9 2104 2112 10.1161/ATVBAHA.111.241463 22796579
39. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS, Nat Struct Mol Biol 2004 11 5 412 419 10.1038/nsmb767 15098021 (Pubitemid 38568944)
40. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA, Curr Opin Lipidol 1996 7 69 76 10.1097/00041433-199604000-00004 8743898 (Pubitemid 26167018)
41. Purification of human serum paraoxonase/arylesterase.Evidence for one esterase catalyzing both activities. Gan KN, Smolen A, Eckerson HW, La Du BN, Drug Metab Dispos 1991 19 1 100 106 1673382
42. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides. Petraki MP, Mantani PT, Tselepis AD, Curr Pharm Des 2009 15 27 3146 3166 10.2174/138161209789057977 19754388